Abstract library

76 results for "Delle fave".
#132 Correlation of Ki-67 proliferative index with pathological features and outcome in pancreatic endocrine tumors
Introduction: Information on relationships between Ki-67 values and clinicopathological features in pancreatic endocrine tumors (PETs) is scant and comes mostly from a small series.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Alessandro Zerbi
#254 Treatment of Pancreatic Neuroendocrine Neoplasms: Data from a Prospective Observational Multicenter Study
Introduction: Information on treatment of pancreatic neurendocrine neoplasms (PNN) comes mostly from small, retrospective studies on highly selected patients.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Alessandro Zerbi
#885 The Role of Combined 68Ga-DOTATOC and 18F-FDG PET/CT in Patients with Pancreatic Neuroendocrine Tumors
Introduction: The value of combined (68)Ga-DOTATOC (68Ga) and (18)F-FDG (18FDG) PET/CT in diagnosis and staging of pancreatic NET is still unclear.
Conference: 11th Annual ENETS Conference (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Stefano Partelli
#921 Combined Therapy with RAD001 e BEZ235 Overcomes Resistance of PET Cells to mTOR Inhibition
Introduction: Since the PI3K/Akt/mTOR proliferation axis is often deregulated in PETs, the mTORC1 complex inhibitor Everolimus (RAD001) represents an effective treatment for PETs. However, RAD001 leads to a re-activation of PI3K activity and phosphorylation of Akt, which may promote resistance to the treatment. Thus, direct inhibition of PI3K may represent a novel potential target for PETs.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Dr Gabriele Capurso
Keywords: mTOR, PI3K, resistance
#937 Real-World Study on Everolimus in Advanced, Progressive Neuroendocrine Tumors
Introduction: Everolimus (EVE) is a valid therapeutic option for neuroendocrine tumors (NETs). However, data in the “real-world” setting outside regulatory trials are scant.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: Francesco Panzuto
#951 SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)
Introduction: Somatostatin analogs can reduce incidence/severity of CS symptoms but their impact on pt satisfaction needs further investigation.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Professor Philippe Ruszniewski
Keywords: PRO
#955 Usefulness of the WHO Classification and of the ENETS TNM Staging System to Predict Prognosis in Patients with Rectal NENs
Introduction: WHO classification and TNM staging system have been proposed for rectal neuroendocrine neoplasia (NENs). However, their prognostic accuracy is not validated yet.
Conference: 11th Annual ENETS Conference (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Professor Gianfranco Delle Fave
#1088 Functional Imaging Tests versus Computed Tomography Scan: Detection of New Metastases and Clinical Usefulness in Digestive Neuroendocrine Neoplasms Follow-Up
Introduction: Digestive Neuroendocrine Neoplasms (DNENs) express in 80% of cases somatostatin receptors (SSTRs) detected by functional imaging tests (FITs). FITs are needed at diagnosis to define therapy but their role in follow-up (FU) is unclear
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: MD, PhD Elettra Merola
Authors: Merola E, Panzuto F, Capurso G, Kump P, ...
#1100 Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A/P16) Polymorphisms and Risk of Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) represent only 1% of all pancreatic neoplasms by incidence, but 10% by prevalence. Family history of cancer is the only established risk factor so far. The impact of germline genetic variability on PNET risk is poorly understood.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Federico Canzian
#1103 Risk and Protective Factors for Midgut Carcinoid Tumours: A Case-Control Study of Prospectively Evaluated Patients
Introduction: The incidence of midgut carcinoid tumours is on the rise, but few studies have investigated risk factors for their occurrence.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Doctor Maria Rinzivillo